Jouve JL, et al. - In patients with advanced hepatocellular carcinoma (HCC), researchers compared the respective clinical outcomes of sorafenib-pravastatin combination vs sorafenib alone. For this investigation, they randomly assigned Child-Pugh A patients with advanced HCC who were naive to systemic treatment (n = 323) to sorafenib-pravastatin combination (n = 162) or sorafenib alone (n = 161) treatments. Three hundred twelve patients received at least one dose of study treatment after randomization. In patients with advanced HCC, the addition of pravastatin to sorafenib did not improve survival. Diarrhea was the main toxicity, while severe nausea-vomiting was rare, and there was no toxic death to deplore.